BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. BioNTech ( NASDAQ:BNTX – Get Free Report ) last released its earnings results on Monday, November 4th.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) climbed 5.4% mid-day Tuesday as remarks by RFK Jr, who clarified his stance as not being anti-vaccine or anti-industry, appeared to bolster investor ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

After hours: 7:46:26 p.m. EST ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...